CN110483504B - 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 - Google Patents
以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 Download PDFInfo
- Publication number
- CN110483504B CN110483504B CN201910712828.2A CN201910712828A CN110483504B CN 110483504 B CN110483504 B CN 110483504B CN 201910712828 A CN201910712828 A CN 201910712828A CN 110483504 B CN110483504 B CN 110483504B
- Authority
- CN
- China
- Prior art keywords
- naphthyl
- pyridine
- imidazole
- aldehyde
- dmf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 title claims abstract description 109
- CGKIWDGOFLFAEZ-UHFFFAOYSA-N 2-naphthalen-2-yl-1h-imidazole Chemical compound C1=CNC(C=2C=C3C=CC=CC3=CC=2)=N1 CGKIWDGOFLFAEZ-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 19
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000006170 formylation reaction Methods 0.000 title claims abstract description 17
- 230000022244 formylation Effects 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- 238000010276 construction Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 4
- SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 229910001882 dioxygen Inorganic materials 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- MHMQWLFOKMOGLI-UHFFFAOYSA-N 2-naphthalen-2-ylimidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=CC(C3=CN4C=CC=CC4=N3)=CC=C21 MHMQWLFOKMOGLI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 3
- KIVZLYHQDAQUKX-UHFFFAOYSA-N 2-naphthalen-2-ylimidazo[1,2-a]pyridine-3-carbaldehyde Chemical compound C1=CC=CC2=CC(C3=C(N4C=CC=CC4=N3)C=O)=CC=C21 KIVZLYHQDAQUKX-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- -1 benzodiazepine compound Chemical class 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910712828.2A CN110483504B (zh) | 2019-08-02 | 2019-08-02 | 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910712828.2A CN110483504B (zh) | 2019-08-02 | 2019-08-02 | 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110483504A CN110483504A (zh) | 2019-11-22 |
CN110483504B true CN110483504B (zh) | 2022-04-26 |
Family
ID=68549228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910712828.2A Active CN110483504B (zh) | 2019-08-02 | 2019-08-02 | 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110483504B (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1401836B1 (en) * | 2001-06-21 | 2006-08-23 | SmithKline Beecham Corporation | Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
RS52060B (en) * | 2006-01-25 | 2012-04-30 | Sanofi | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES |
AU2009303335B2 (en) * | 2008-10-09 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
JP5621771B2 (ja) * | 2009-06-17 | 2014-11-12 | 小野薬品工業株式会社 | 新規なイミダゾピリジン化合物 |
CN102358739B (zh) * | 2011-04-29 | 2013-02-20 | 中国科学院广州生物医药与健康研究院 | 咪唑[1,2-a]吡啶和咪唑醛类化合物的合成方法 |
CN103435609B (zh) * | 2013-09-09 | 2015-06-03 | 东北师范大学 | 铜催化的咪唑并[1,2-a]吡啶-3-甲醛类化合物的合成方法 |
-
2019
- 2019-08-02 CN CN201910712828.2A patent/CN110483504B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110483504A (zh) | 2019-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109705013B (zh) | 一种1-(4-甲基苄基)-3-氨基-4-甲硒基马来酰亚胺化合物及制备方法 | |
CN115490697B (zh) | 一种手性氮杂螺[4,5]-癸胺的不对称合成方法 | |
CN109265475B (zh) | 一种多取代芳基乙烯硼酸频哪醇酯衍生物的制备方法 | |
CN111620808B (zh) | 一种2-醛基吲哚类化合物及其制备方法 | |
Meshram et al. | Bismuthtriflate-catalyzed Reaction of N-Alkylisatins with Allyltrimethylsilane | |
CN111978237B (zh) | 一种3-吗啉基-4-芳硒基马来酰亚胺化合物的制备方法 | |
CN110483504B (zh) | 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法 | |
CN110483506B (zh) | 以DMF为甲酰化试剂构建2-(2-噻吩基)咪唑[1,2-a]吡啶-3-醛的新方法 | |
CN108558785B (zh) | 一种5-芳基-2-芳硒基-1,3-噁唑化合物及制备方法 | |
CN114292153B (zh) | 一种芳基卤化物的高效合成方法 | |
CN110317170B (zh) | 一种3-菲啶基甲酸丙酯类化合物的绿色合成方法 | |
CN110862421B (zh) | 含氮杂环二茂铁衍生物的合成方法 | |
CN110437277B (zh) | 一种磷酸烯基酯类化合物的合成方法 | |
CN109851599B (zh) | 一种2-氨基苯并呋喃化合物的制备方法 | |
CN109369678B (zh) | 一种天然产物异构体(-)-6-epi-Porantheridine的合成方法 | |
CN116514624B (zh) | 一种n-单氟甲基羰基化合物及其制备方法 | |
CN114133389B (zh) | 制备异吲哚啉-1-酮并环及其类似物的方法 | |
CN110372616B (zh) | 一种n1位取代的1,2,3-三唑类衍生物的合成方法 | |
CN110256349B (zh) | 多取代吡唑及其制备方法 | |
CN113200980B (zh) | 一种银催化合成中氮茚类化合物的方法 | |
CN112824411B (zh) | 一类桥环异吲哚啉酮衍生物及其制备方法和用途 | |
CN115215803B (zh) | 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法 | |
CN112745275B (zh) | 1,3,4-恶二唑杂环化合物的合成方法 | |
CN111620868B (zh) | 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法 | |
CN110372696A (zh) | 一种以DMF为甲酰化试剂构建咪唑[1,2-a]吡啶-3-醛的新方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191122 Assignee: GUANGXI AGLYCONE PLANT PRODUCTS Co.,Ltd. Assignor: GUILIN University OF TECHNOLOGY Contract record no.: X2023980044262 Denomination of invention: A new method for constructing 2- (2-naphthyl) imidazole [1,2-a] pyridine-3-aldehyde using DMF as a formylation reagent Granted publication date: 20220426 License type: Common License Record date: 20231025 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20191122 Assignee: Guangxi Jikuan Energy Technology Co.,Ltd. Assignor: GUILIN University OF TECHNOLOGY Contract record no.: X2023980044948 Denomination of invention: A new method for constructing 2- (2-naphthyl) imidazole [1,2-a] pyridine-3-aldehyde using DMF as a formylation reagent Granted publication date: 20220426 License type: Common License Record date: 20231101 |